Meridia (sibutramine hydrochloride): Early Communication about an Ongoing Safety Review
November 20th, 2009 · No Comments
FDA is reviewing preliminary data from a recent study suggesting that patients using sibutramine have a higher number of cardiovascular events (heart attack, stroke, resuscitated cardiac arrest, or death) than patients using a placebo.
Tags: FDA · FDA Alerts
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must log in to post a comment.